NuPathe Inc. (PATH) said its NDA for Zelrix has been accepted for filing by the U.S. Food and Drug Administration. NuPathe submitted the Zelrix NDA on October 29, 2010.
The company expects to receive a Prescription Drug User Fee Act date, the target date for the FDA to complete its review of the NDA, of August 29, 2011.
Zelrix is the first ever submission to the FDA of a transdermal patch for the treatment of migraine.
For comments and feedback contact: editorial@rttnews.com
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.